Go to the briefing

Let the unanswered point stay visible

Which signs call for another question?

What part of the offer still needs an answer? Name it before paying. A neat page can leave the basic questions unresolved.

Make your call · a learning step

Look for reasons to pause an offer

Under United States federal law in September 2026, a valid prescription was required before supplying medicine that needs a prescription.

Note A

The medicine order written by a licensed prescriber is called a prescription. Ask who will assess you before that order is written.

Do not treat a checkout page as the assessment.

Approval language that does not add up

Claiming FDA approval for a compounded drug is false, under FDA guidance checked in September 2026.

Note B

Compounding is the name for preparing medicine, including mixing it, in response to an order.

The Food and Drug Administration reviews drugs at the federal level; FDA is its short name.

The words “for research use only” on a label describe research purposes, rather than treatment of people. In letters reviewed in September 2026, FDA said sellers used such labels while also describing products as medicines for people.

Note C

Those letters state FDA’s claims about specific businesses. They are not court decisions.

Do not treat research wording as permission to use a product for your care. Ask about the exact medicine and its approval.

Pressure to pay before the details are clear

Federal Trade Commission guidance checked in September 2026 flags demands to pay only by wire, cryptocurrency, payment app or gift card.

Note D

The same warning also covers bank transfers demanded as the only way to pay.

Ask for the pharmacy name, the full quote and the terms. An unanswered question can stay open without you agreeing to anything.

Return to the care-route checks

Page notes

  1. Federal prescription requirement

    The order must come from a practitioner licensed to prescribe it.

    Back to the briefing
  2. FDA on false approval claims

    The claim of approval is the problem being identified, not compounding as a whole.

    Back to the briefing
  3. FDA letter explaining intended human use

    The letter states FDA’s claims about one business. FDA looked at what the offer said about use in people, as well as the research label.

    Back to the briefing
  4. Federal Trade Commission on payment demands

    The concern is being told that only these payment routes are available.

    Back to the briefing